Hepcidin in anemia and inflammation in chronic kidney disease

Kidney and Blood Pressure Research

Volumn 30, Issue 1, 2007, Pages 15-30

  Malyszko, Jolanta ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chronic kidney disease; Dialysis patients, anemia and iron balance; Hepcidin; Hepcidin, anemia; Hepcidin, inflammation; Iron balance, regulation

Indexed keywords

ERYTHROPOIETIN; HEPCIDIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CELL AGING; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; DIALYSIS; ERYTHROPOIESIS; GENE MUTATION; HEMODIALYSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON BALANCE; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON THERAPY; IRON TRANSPORT; LIVER FUNCTION; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; CHRONIC DISEASE; HUMANS; INFLAMMATION; IRON; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; RENAL DIALYSIS;

EID: 33847068208     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098522     Document Type: Review

References (112)

1. Brittenham GM: Disorders of iron metabolism: Iron deficiency and overload; in Hoffman R, Benz EJ Jr, Shattil SJ, et al (eds): Hematology Basic Principles and Practice, ed 2. New York, Churchill Livingstone, 1995.
2. Bridges KR, Seligman PA: Disorders of iron metabolism; in Handin RI, Lux SE, Stossel TP (eds): Blood: Principles and Practice of Hematology, chapt 49. Philadelphia, Lippincott, 1995.
3. Roy CN, Enns CA: Iron homeostasis: new tales from the crypt. Blood 2000;96:4020-4027.
4. Philpott CC: Molecular aspects of iron absorption: insights into the role of HFE in hemochromatosis. Hepatology 2002;35:993-1001.
5. Finch CA, Huebers H: Perspectives in iron metabolism. N Engl J Med 1982;306:1520-1528.
6. Bothwell TH: Overview and mechanisms of iron regulation. Nutr Rev 1995:53:237-245.
7. Cook JD: Clinical evaluation of iron deficiency. Semin Hematol 1982;19:6-18.
8. Worwood M: Overview of iron metabolism at a molecular level. J Intern Med 1989;226:381-391.
9. Deaglio S, Capobianco A, Cali A, Bellora F: Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood 2002;100:3782-3789.
10. Robb A, Wessling-Resnick M: Regulation of transferrin receptor 2 protein levels by transferrin. Blood 2004;104:4294-4299.
11. Johnson MB, Enns CA: Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 2004;104:4287-4293.
12. Kawabata H, Nakamaki T, Ikonomi P, Smith RD: Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood 2001;98:2714-2719.
13. Hintze KJ, Theil EC: DNA and mRNA elements with complementary responses to hemin, antioxidant inducers, and iron control ferritin-L expression. Proc Natl Acad Sci USA 2005;102:15048-15052.
14. Torti FM, Torti SV: Regulation of ferritin genes and protein. Blood 2002;99:3505.
15. Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ, Huebers HA: Plasma ferritin determination as a diagnostic tool West J Med 1986;145:657-663.
16. Abboud S, Haile DJ: A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906-19912.
17. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC: The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1:191-200.
18. Chen H, Su T, Attieh ZK, Fox TC, McKie AT, Anderson GJ, Vulpe CD: Systemic regulation of hephaestin and Ireg1 revealed in studies of genetic and nutritional iron deficiency. Blood 2003;102:1893-1899.
19. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F: Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 2005;106:3979-3984.
20. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
21. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T: Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005;106:2196-2199.
22. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F: The presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and downregulated by hepcidin. Blood 2005;106:3979-3984.
23. Frazer DM, Anderson GJ: The orchestration of body iron intake: How and where do enterocytes receive their cues? Blood Cells Moll Dis 2003;30:288-297.
24. Andrews NC: Molecular control of iron metabolism. Best Pract Res Clin Haematol 2005;18:159-169.
25. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
26. Krause A, Neitz S, Magert HJ, Schyltz A, Forssmann WG, Schulz-Knappe P, Adermann L: LEAP-1, a novel highly disulfide-bonded human peptide exhibits antimicrobial activity. FEBS Lett 2000;480:147-150.
27. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W: Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735-743.
28. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA: Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482-488.
29. Eschbach JW, Cook JD, Scribner BH, Finch CA: Iron balance in hemodialysis patients. Ann Intern Med 1977;87:710-713.
30. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, Dominguez-Cabrera C, Hortal-Cascn L, Perez-Borges P, Vega-Diaz N, Saavedra-Santana P, Palop-Cubillo L: Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999;34:508-513. 31 Nissenson AR: Achieving target hematocrit in dialysis patients: new concepts in iron management. Am J Kidney Dis 1997;30:907-911.
31. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783-788.
32. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 knockout mice. Proc Natl Acad Sci USA 2001;98:8780-8785.
33. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-7819.
34. Hunter HN, Fulton DB, Ganz T, Vogel HJ: The solution structure of human hepcidin, a peptide-hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis J Biol Chem 2002;277:37597-37603.
35. Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W: The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 2005;184:361-370.
36. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S: Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002;99:4596-4601.
37. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, Andrews NC, Vaulont S: Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003;34:97-101.
38. Laftah AH, Ramesh B, Simpson RJ, Solanky N, Bahram S, Schumann K, Debnam ES, Srai SK: Effect of hepcidin on intestinal iron absorption in mice. Blood 2004;103:3940-3944.
39. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276.
40. Ganz T: Hepcidin - a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171-182.
41. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-1044.
42. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S: Hepcidin a new iron regulatory peptide. Blood Cells Mol Dis 2002;29:327-335.
43. Safran M, Kaelin WG Jr: HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003;111:779-783.
44. Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, Gilot D, Boudjema K, Guguen-Guillouzo C, Brissot P, Loreal O, Ilyin G: C/EBP-α regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. J Biol Chem 2002;277:41163-41170.
45. Roy CN, Andrews NC: Anemia of inflammation: the hepcidin link. Curr Opin Hematol 2005;12:107-111.
46. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C: Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-22.
47. Morley JJ, Kushner I: Serum C-reactive protein levels in disease. Ann NY Acad Sci 1982;389:406-418.
48. Kushner I: The phenomenon of the acute phase response. Ann NY Acad Sci 1982;389:39-48.
49. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
50. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461.
51. Shike H, Lauth X, Westerman ME, Ostland VE, Carlberg JM, van Olst JC, Shimizu C, Bulet P, Burns JC: Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. Eur J Biochem 2002;269:2232-2237.
52. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-7255.
53. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH: Study of the molecular mechanisms of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987;79:1635-1641.
54. Wrighting DM, Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood 2006;108:3204-3209.
55. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time course analysis of hepcidin, serum iron, and plasma cytokine levels in human injected with LPS. Blood 2005;106:1864-1866.
56. Aisen P, Enns C, Wessling-Resnick M: Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001;33:940-959.
57. Dey R, Datta SC: Leishmanial glycosomes contain superoxide dismutase. Biochem J 1994;301:317-319.
58. Zhang Y, Lathigra R, Garbe T, Catty D, Young D: Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of mycobacterium tuberculosis. Mol Microbiol 1991;5:381-391.
59. Singh PK, Parsek MR, Greenberg EP, Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552-555.
60. Risso A: Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leukoc Biol 2000;68:785-792.
61. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ: Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004;22:181-215.
62. Ashrafian H: Hepcidin: the missing link between hemochromatosis and infections. Infect Immun 2003;71:6693-6700.
63. Xiong S, She H, Takeuchi H, Han B, Engelhardt JF, Barton CH, Zandi E, Giulivi C, Tsukamoto H: Signaling role of intracellular iron in NF-κB activation. J Biol Chem 2003;278:17646-17654.
64. 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci USA 2004;101:9263-9265.
65. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC: Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776-3781.
66. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113:1251-1253.
67. Cash JM, Sears DA: The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med 1989;87:638-644.
68. Schilling RF: Anemia of chronic disease: a misnomer. Ann Intern Med 1991;115:572-573.
69. Weiss G: Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002;16:87-96.
70. Means RT Jr: Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003;2:116-121.
71. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
72. Opasich C, Cazzola M, Scelsi L, et al: Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232-2237.
73. Fleming RE, Sly WS: Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001;98:8160-8162. 75 Dallalio G, Law E, Means T: Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin. Blood 2006;107:2702-2704.
74. Katsume A, Saito H, Yamada Y: Anti-interleukin-6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-311.
75. Van Gameren MM, Willemse PH, Mulder NH: Effects of recombinant human interleukin-6 in cancer patients a phase I-II study. Blood 1994;84:1434-1441.
76. Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, de Vries EG: Recombinant human interleukin-6 induces a rapid reversible anemia in cancer patients. Blood 1995;86:900-905.
77. Schindler R, Boenisch O, Fischer C, Frei U: Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000;53:452-459.
78. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, Capuano A, Andreucci M, Balletta MM, Guida B, Tetta C, Collaborative Study Group on SMC Membrane: Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002;39:266-273.
79. Tielemans C, Husson C, Schurmans T, Gastaldello K, Madhoun P, Delville JP, Marchant A, Goldman M, Vanherweghem JL: Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int 1996;49:236-243.
80. Hosoya N, Sakai K: Backdiffusion rather than backfiltration enhances endotoxin transport through highly permeable dialysis membranes. ASAIO Trans 1990;36:M311.
81. Ayus JC, Sheikh-Hamad D: Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998;9:1314-1317.
82. Cappelli G, Tetta C, Canaud B: Is biofilm a cause of silent chronic inflammation in haemodialysis patients? A fascinating working hypothesis. Nephrol Dial Transplant 2005;20:266-270.
83. Bemelmans MH, Gouma DJ, Buurman WA: Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993;150:2007-2017.
84. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, Kenny AJ, Saklatvaa J: Fate of injected interleukin-1 in rats: sequestration and degradation in the kidney. Cytokine 1990;2:416-422.
85. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, Metelli MR, Giovannini L, Tetta C, Palla R: C-reactive protein in patients with chronic renal diseases. Ren Fail 2001;23:551-562.
86. Stenvinkel P, Heimburger O, Wang T, Lindholm B, Bergstrom J, Elinder CG: High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999;34:1083-1088.
87. Chung SH, Heimburger O, Stenvinkel P, Bergstrom J, Lindholm B: Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001;16:2240-2245.
88. Pecoits-Filho R, Heimburger O, Barany P, Suliman M: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-1218.
89. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
90. Shah SV, Alam MG: Role of iron in atherosclerosis. Am J Kidney Dis 2003;41(suppl 1):S80-S83.
91. Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colon formation in uremic patients with inflammatory disease. Role of IFN-γ and TNF-α. J Investig Med 1999;47:204-211.
92. Malyszko J, Malyszko JS, Hryszko T, Pawlak K, Mysliwiec M: Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol 2005;25:586-590.
93. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR: Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004;42:387-389.
94. Dallalio G, Fleury T, Means T: Serum hepcidin in clinical specimens. Br J Haematol 2003;122:996-1000.
95. Sunder-Plassmann G, Horl WH: Erythropoietin and iron. Clin Nephrol 1997;47:141-157.
96. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;4:7251-7255.
97. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, Ropert M, Jacquelinet S, Courselaud B, Ganz T, Brissot P, Loreal O: Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels and hepatic function. Blood 2005;106:746-748.
98. Aoki CA, Rossaro L, Ramsamooj RR, Brandhagen D, Burritt MF, Bowlus CL: Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 2005;39:71-74.
99. Tomosugi N, Kawabata H, Wakatabe R, et al: Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381-1387.
100. Wang GL, Semenza GL: Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol 1996;3:156-162.
101. Langsetmo I, Nichols B, Seeley T, Stephenson B, Klaus S, Lin A, Liu DY: FG-2216 corrects anemia and improves iron utilization in a rat model of anemia of chronic disease: comparison to darbepoetin. J Am Soc Nephrol 2005;16:481A.
102. Seeley TW, Langsetmo I, Stephenson R, Pacleb J, Gervasi D, Lomonsgod E, Klaus S, Liu DY: FG-2216: Tumor progression studies and correction of anemia of chronic disease in xenograft model. J Am Soc Nephrol 2005;16:481A.
103. Malyszko J, Malyszko JS Pawlak K, Mysliwiec M: Hepcidin, iron status and renal function in chronic renal failure, kidney transplantation and hemodialysis. Am J Hematol 2006;81:832-837.
104. Malyszko J, Malyszko JS Pawlak K, Mysliwiec M: Hepcidin, an acute phase protein and a marker of inflammation in kidney transplant recipients with and without coronary artery disease. Transplant Proc 2006, doi 10.1016/ jtransproceed. 2006.06.137
105. Brookes MJ, Sharma NK, Tselepis C, Iqbal TH: Serum pro-hepcidin: measuring active hepcidin or a non-functional precursor? Gut 2005;54:169-170.
106. Malyszko J, Malyszko JS, Pawlak K, Brzosko S, Rams L, Mysliwiec M: Hepcidin: a link between anemia and inflammation peritoneally dialyzed patients? ISPD Congress, Hong Kong 2006, p 377.
107. Pertosa G, Simone S, Corciulo R, Pontrelli P, et al: Hepcidin serum levels, functional iron deficiency and erythropoietin hyporesponsiveness in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2005;16:476A.
108. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, Goldberg YP, Sakellaropoulos N, Ganz T, Nemeth E: Hepcidin in iron overload disorders. Blood 2005;105:4103-4105.
109. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T: Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005;105:1797-1802.
110. Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D: Novel urine hepcidin assay by mass spectrometry. Blood 2005;106:3268-3270.
111. Tomosugi N, Kitagawa K, Takahashi N, Sugai S, Ishikawa I: Diagnostic potential for a tear proteonomic patterns in Sjögren's syndrome. J Proteosome Res 2005;4:820-825.
112. Pietrangelo A, Trautwein C: Mechanisms of disease: the role of hepcidin in iron homeostasis - implications for hemochromatosis and other disorders. Nat Clin Practice Gastrol Hepatol 2004;1:39-45; authors' reply 2005;2:E2 doi 10.1038/ncpgasthep0122.